Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

GA-VAX

Financiado

Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS...

Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stage Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that is triggered by protein aggregation in the brain and spinal cord motor neurons that leads to respiratory failure within 2-5 years. The best available dr... ver más

31/01/2025

BUNDESMINISTERIUM...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

BUNDESMINISTERIUM FUER GESUNDHEIT No se ha especificado una descripción o un objeto social para esta compañía.

Ver 2 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-03-22

HORIZON-EIC-2021-TRANSITIONOPEN-01: EIC Transition Open 2021 Scope:The EIC Transition Open aims at funding innovation activities that go beyond the experimental...

I+D

Cerrada hace 3 años

0% 100% 100%

2 Participantes

BUNDESMINISTERIUM FUER GESUN...

1.05M€ | Lider

INTRAVACC

1.45M€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CNS2023-144342 Herramientas diagnósticas, pronósticas y terapéuticas 200K€ Cerrado

BIO2016-78310-R AGREGACION DE PROTEINAS: ESTRATEGIAS TERAPEUTICAS, DIAGNOSTI... 309K€ Cerrado

C9-T Immunity Do T cells link loss and gain-of-function mechanism in C9orf... 1M€ Cerrado

PTQ-14-07332 Diseño y aplicación de técnicas de secuenciación masiva para... 53K€ Cerrado

DPR-VAX Dipeptide Repeat Vaccine to prevent ALS and FTD in C9orf72 m... 150K€ Cerrado

BES-2016-076410 NUEVAS MOLECULAS MULTIDIANA Y TERANOSTICAS PARA EL DIAGNOSTI... 93K€ Cerrado

Duración del proyecto: 34 meses Fecha Inicio: 2022-03-22
Fecha Fin: 2025-01-31

Líder del proyecto

BUNDESMINISTERIUM FUER GESUNDHEIT No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 2M€

Descripción del proyecto Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that is triggered by protein aggregation in the brain and spinal cord motor neurons that leads to respiratory failure within 2-5 years. The best available drug extends life by ~3 months. ALS strikes about 1 in 500 people mostly for unknown reasons, but 5-10% of cases in Caucasians are caused by a mutation in the C9orf72 gene. We have shown that this mutation leads to expression of large aggregating poly-Glycine-Alanine (poly-GA), which triggers downstream pathology. We developed a poly-GA peptide vaccine that reduces aggregates and largely prevents motor deficits in a mouse model. When starting vaccination in already symptomatic mice, our vaccine reduces neuronal damage to a similar extent. Since regular lifelong vaccination is required to maintain sufficient antibody levels, GA-VAX is an attractive business case in the orphan disease space with ~2500 prevalent C9orf72 ALS cases in the US, DE, IT, FR, ES, UK. ~9000 mutation carriers at risk to develop disease within 10 years could benefit even more from our approach. A joint venture established by Intravacc and DZNE will bring together the right resources to advance this promising treatment approach towards clinical evaluation. Intravacc contributes know-how for production and clinical development of peptide/carrier conjugate vaccines, DZNE provides in depth knowledge of disease pathology as well as all necessary model systems and assays. Together we will setup GMP manufacturing for the antigen and conduct pivotal toxicology and efficacy studies in animals in accordance with regulatory requirements by EMA and FDA. This will allow us to compile a clinical trial application in C9orf72 ALS patients. In addition, we will use this data-package to raise capital for the phase 1 trial from a patient organization or investor for further de-risking or, preferentially, directly partner with a larger pharma company to bring GA-VAX to the market.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores